Digoxin Immune Fab

Biochem/physiol Actions T-5224 is an orally active, selective AP-1 transcription complex c-Fos/c-Jun inhibitor that blocks c-Fos and c-Jun DNA-binding activity, but not that of C/EBP&#945:, ATF-2 (bZIP domain), MyoD (bHLH domain), Sp-1 (ZF domain)

Biochem/physiol Actions T-5224 is an orally active, selective AP-1 transcription complex c-Fos/c-Jun inhibitor that blocks c-Fos and c-Jun DNA-binding activity, but not that of C/EBP&#945:, ATF-2 (bZIP domain), MyoD (bHLH domain), Sp-1 (ZF domain)

A diglycan that binds galectins-1, -3, -8, and -9 with Kd values between 24 and 78 &microM used to investigate the roles of these galectins in cell signaling and carcinogenesis.

A diglycan that binds galectins-1, -3, -8, and -9 with Kd values between 24 and 78 &microM used to investigate the roles of these galectins in cell signaling and carcinogenesis.

A diglycan that binds galectins-1, -3, -8, and -9 with Kd values between 24 and 78 &microM used to investigate the roles of these galectins in cell signaling and carcinogenesis.

Immunogen 16 amino acids near the center of human VENTX. Application Used as a blocking peptide in immunoblotting applications.

YC-1 has been used as a hypoxia-inducible factor 1α (HIF-1α) inhibitor:to reduce hypoxia induced Jagged1 expression in cardiomyocytes (CMs) to study its effect on progenitor expansion and CD34+ and side population (SP) cell phenotype and on the

YC-1 has been used as a hypoxia-inducible factor 1α (HIF-1α) inhibitor:to reduce hypoxia induced Jagged1 expression in cardiomyocytes (CMs) to study its effect on progenitor expansion and CD34+ and side population (SP) cell phenotype and on the

YC-1 has been used as a hypoxia-inducible factor 1α (HIF-1α) inhibitor:to reduce hypoxia induced Jagged1 expression in cardiomyocytes (CMs) to study its effect on progenitor expansion and CD34+ and side population (SP) cell phenotype and on the

YC-1 has been used as a hypoxia-inducible factor 1α (HIF-1α) inhibitor:to reduce hypoxia induced Jagged1 expression in cardiomyocytes (CMs) to study its effect on progenitor expansion and CD34+ and side population (SP) cell phenotype and on the